ONM-100 Addresses Unmet Need for Real-Time Cancer Resection Imaging
ON IMAGING PLATFORM
ON IMAGING PLATFORM
- Currently, surgeons rely on relatively imprecise imaging results conducted prior to surgery to identify the general location, scope of tumor, and lymph node invasion
- In the OR, surgeons typically rely on use of cameras, visual inspection and palpation to identify tumors, and the margin between tumor and normal tissue
- Literature and our clinical experience indicate that the current standard of care for tumor resection can result in positive margins and satellite tumors left behind
- ONM-100 provides surgeons with real-time, sharp visualization of tumors improving surgical outcomes
ONM-100 Clinical Success Demonstrates Precision of Micelle Technology
Key Clinical Findings:
- Very well tolerated, no product related SAEs
- Florescence seen across all 6 tumor types in ~45pts- Breast,Colorectal,Esophageal,Head&Neck, Ovarian, Prostate
- Clear, real-time delineation of tumor
- Phase 1 results:- 100%responserate(abilitytoidentifytumors)- IdentifiedoccultdiseasemissedbySOCin ~30% of patients
- Dose proportional PK, 44±16 hr half-life
- FDAFastTrackdesignation
ONM-300: Technology Also Employed in Next Generation PET Imaging Agent
- IV injectable whole body non-invasive tumor imaging using 64Cu
- Precision imaging of tumors poorly imaged by FDG-PET incl. brain
- Eliminates false positives from brown fat, inflammation, striated muscle
And...Clinical Imaging Experience Validates Cancer Therapeutic Platforms and Associated Programs
- IV injectable whole body non-invasive tumor imaging using 64Cu
- Precision imaging of tumors poorly imaged by FDG-PET incl. brain
- Eliminates false positives from brown fat, inflammation, striated muscle
